ENPICOM will expand its IGX Platform to enable new liability analyses for antibody discovery workflows
‘s-Hertogenbosch, The Netherlands, June 10, 2021 – ENPICOM, an innovative bioinformatics software engineering company, announced the upcoming expansion of the IGX Platform’s capabilities towards advanced liability prediction. At the Antibody Engineering and Therapeutics virtual conference, the company revealed its plans to integrate the Structural Antibody Prediction Platform (SAbPred) developed by researchers at the University of Oxford.
“SAbPred is a widely recognized and validated tool developed by experts in molecular biology. While our team harbors a lot of knowledge in bioinformatics and software engineering, we believe this powerful combination brings the best of the two worlds. We are elevating our current platform capabilities and deliver an exceptional experience to antibody and vaccine developers looking for a more rapid, efficient, and reliable antibody discovery solution.” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM.
“We’re very excited to see Oxford Protein Informatics Group’s SabPred tools incorporated into ENPICOM’s IGX Platform. This collaboration will open the door for new users to apply our software to the structural analysis of antibodies.” said Fergus Boyles, Research Software Engineer at University of Oxford.
Enabling structural liability analysis at scale
Oxford researchers have developed SAbPred to perform various predictions of antibody properties that can support the discovery process and antibody design. The software helps study antibody properties and generate valuable information for developability potential of antibody candidates. SAbPred is currently used by leading biopharmaceutical companies to improve the design of antibody-based therapeutics.
By integrating SAbPred tools into the IGX Platform, ENPICOM allows scientists to apply the sophisticated algorithms to analyze high-throughput sequencing data inside the scalable and intuitive environment. This integration unlocks new antibody discovery workflows like performing structural analysis of proteins of interest and annotating important liability characteristics to select antibody candidates with good developability properties.
“The integration of SAbBox technology with ENPICOM’s IGX platform is great case study for impact from research at the Oxford University. We look forward to this launch as it will provide new ways of accessing the SabPred tools on a cloud-based platform.” said Sandeep Singh, Senior Licensing and Ventures Manager at Oxford University Innovation.
To learn more about the announcement at the Antibody Engineering and Therapeutics virtual conference, view the on-demand recording of the speaking session here.
ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of over 25 experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system, to biotech and global pharmaceutical companies focusing on the discovery and development of novel immunotherapies and vaccines.
Leveraging a unique mix of immunology knowledge, bioinformatics method development, and software engineering skills, ENPICOM offers a world-class repertoire sequencing data analysis solution – the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors. In collaboration with DDL Diagnostic Laboratory, ENPICOM delivers full immune repertoire sequencing and analysis service.
Marketing Communications Manager
+31 85 250 0575